1 / 17

RESUSCITATIVE HYPOTHERMIA ACADEMIC INDUSTRY ROUNDTABLE Hypothermia: future directions

RESUSCITATIVE HYPOTHERMIA ACADEMIC INDUSTRY ROUNDTABLE Hypothermia: future directions. Midori A. Yenari, MD Depts. of Neurosurgery & Neurology Stanford Stroke Center & Stanford University Stanford, CA. Introduction. Hypothermia is a robust neuroprotectant.

terah
Télécharger la présentation

RESUSCITATIVE HYPOTHERMIA ACADEMIC INDUSTRY ROUNDTABLE Hypothermia: future directions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RESUSCITATIVE HYPOTHERMIA ACADEMIC INDUSTRY ROUNDTABLEHypothermia: future directions Midori A. Yenari, MD Depts. of Neurosurgery & Neurology Stanford Stroke Center & Stanford University Stanford, CA

  2. Introduction • Hypothermia is a robust neuroprotectant. • Compelling pre-clinical data to justify clinical trials • Questions at preclinical level: duration/delay, permanent occlusion, combination with thrombolysis, combination with other treatments?

  3. Summary: Hypothermia in Experimental Stroke • Depth: 34.5C or lower results in comparable neuroprotection, but lower temperatures are associated with compromised hemodynamics; most consistent results with 30-33C • **Duration: At least one hour, provided cooling begins soon after ischemia onset. Several hours (6-12 h) if cooling is delayed by more than several hours • **Delay: consistent protection with 2-3 h delay with at least 2 h cooling; can delay up to 6 h provided cooling is maintained for 1-2d • Long term:protection observed out to 2 mos with 2 h intraischemic cooling, or 1 h delay with prolonged cooling (2d); 70% protection in global model out to 6 mos, but extent of protection decreases over time • **Permanent vs. Temporary: mixed results

  4. Protect against permanent ischemia? Less consistent data compared to temporary ischemia Protects: Intraischemic hypothermia for 6 h ↓infarct size @ 6 h(Baker et al, Exp Neurol 1991) Intraischemic hypothermia for 24 h ↓infarct size @ 48 h (Yamamoto et al, Stroke 2001) ↓ infarct size @ 24 h when cooling (30-34.5C) delayed up to 1 h & maintained for 1 h (Kader et al, Neurosurgery 1992) Doesn’t protect: No difference in infarct size when cooling (33C) was instituted during ischemia, and maintained for 1 h (Ridenour et al, Stroke 1992) No protection when cooling to 30-36C was instituted shortly after occlusion and maintained for 2 h (Morikawa et al, JCBFM 1992)

  5. Optimize duration/delay • Brief intraischemic hypothermia (1-2 h) protects, but also protects when cooling begins 2-3 h after ischemia onset • Prolonging the duration of cooling to several hours seems to lengthen the temporal therapeutic window • What are the limits in rodents? In humans?

  6. Combination hypothermia & rt-PA • Embolic model in rats • Hypothermia (32C), normothermia (37C) or hyperthermia (39C) for 2 h pre/post embolization • rt-PA 2 h after embolization • Angiographic recanalization best @ 39C • rt-PA Rx itself ↓ inf. Size ~50% • @ 48h: largest infarcts (39C), smallest (32C), hypothermia ↓inf. size by ~70% • No further improvement with rt-PA/hypothermia—is lack of difference due to robust protection by hypothermia? • Interaction of rt-PA and temperature? • Can hypothermia prolong the window for rt-PA Rx? Reduce hemorrhage? (Meden et al, Br Res, 1994)

  7. Effect of temperature on clot lysis • rt-PA is the only approved treatment for acute stroke • combination rt-PA and mild hypothermia? • how does temperature influence clot lysis?

  8. Effect of temperature on clot lysis • Thrombin stabilized, 24 h aged clots from whole blood of donor rabbits. • Incubate in sterile PBS at 24, 30, 33, 35, 37 & 40C. • Incubate with rt-PA (concentrations corresponding to serum levels in rabbits given doses of 1, 3 and 6 mg/kg) • Measure pre- and post-incubation weights

  9. Clot lysis is dose dependent • clot lysis is dose dependent • each 1 ug/ml increase in rt-PA increases clot lysis by 4% (Yenari et al, Thrombosis research, 1995)

  10. Clot lysis & temperature • rt-PA: ~0.5% decreased clot lysis/1C drop • control: 0.5% increased in clot lysis/1C drop (Yenari et al, Thrombosis research, 1995)

  11. Combination RX with hypothermia & gene therapy (Zhao et al.) • HSV viral vectors • Overexpress potentially neuroprotective genes • Bcl-2 as a prototypical anti-apoptosis, anti-necrosis gene

  12. Bcl-2, an anti-apoptotic protein, to treat stroke -6-15 h 0 1h 1.5h 5h 48h Inject vector occlude reperfuse end experiment* Delay vector delivery

  13. Striatal Bcl-2 overexpression protects neurons from tMCAO (Lawrence et al, JCBFM, 1995)

  14. Combination Bcl-2 gene therapy & hypothermia 0 1h 2h 5h 48h Inject vectors* Occlude reperfuse end experiment Groups: 33C-control 33C-Bcl-2 37C-control 37C-Bcl-2 Cool to 33C

  15. Hypothermia prolongs the temporal therapeutic for Bcl-2 gene therapy *vs 37ºC-Bcl-2, p<0.01 #vs. 33C-control, p<0.01

  16. Conclusions • Permanent occlusion? • Optimal duration/delay? • Combination Rx with thrombolytics? • Combination Rx with neuroprotectants?

More Related